Vanessa Montes Santos1, Gustavo Nader Marta2,3, Marcella Coelho Mesquita4, Rossana Veronica Mendoza Lopez5, Edla Renata Cavalcante4, Olavo Feher4,6. 1. Hospital Israelita Albert Einstein - Clinical Oncology Unit, São Paulo, Brazil. 2. Department of Radiology and Oncology, Radiation Oncology Unit, Instituto do Câncer do Estado de São Paulo (ICESP), Universidade de São Paulo, Ave. Dr Arnaldo, 251, São Paulo, SP, 01246-000, Brazil. gustavo.marta@hc.fm.usp.br. 3. Department of Radiation Oncology, Hospital Sírio-Libânes, São Paulo, Brazil. gustavo.marta@hc.fm.usp.br. 4. Department of Radiology and Oncology, Clinical Oncology Unit, Instituto do Câncer do Estado de São Paulo (ICESP), Universidade de São Paulo, São Paulo, Brazil. 5. Instituto do Câncer do Estado de São Paulo (ICESP) - Center for Translational Research in Oncology, Universidade de São Paulo, São Paulo, Brazil. 6. Department of Clinical Oncology, Hospital Sírio-Libânes, São Paulo, Brazil.
Abstract
PURPOSE: The standard treatment for newly diagnosed glioblastoma includes maximal safe surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) and maintenance TMZ. The impact of time to start radiation therapy (TRT) on overall survival (OS) in glioblastoma patients is controversial. The study aimed to evaluate the impact of TRT on OS in patients diagnosed with glioblastoma who received standard treatment. METHODS: In this retrospective study, we included patients with confirmed diagnosis of glioblastoma treated from 2011 to 2016. TRT was defined as the time between surgery (biopsy or resection) and the first day of radiation therapy. The endpoint was OS. The patients were divided according to the TRT in three categories: < 30 days, 30-60 days and ≥ 60 days. RESULTS: A total of 134 patients were included with a mean age of 51.82 years (range 19-78 years). Median TRT was 80 days. On univariate and multivariable analysis, we identified age as the only significant independent predictor for OS. There was no statistically significant negative impact of TRT on OS (p = 0.47). CONCLUSIONS: There was no clear evidence that delaying post-operative combined chemoradiotherapy negatively impacts OS, not even for TRT longer than 60 days.
PURPOSE: The standard treatment for newly diagnosed glioblastoma includes maximal safe surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) and maintenance TMZ. The impact of time to start radiation therapy (TRT) on overall survival (OS) in glioblastomapatients is controversial. The study aimed to evaluate the impact of TRT on OS in patients diagnosed with glioblastoma who received standard treatment. METHODS: In this retrospective study, we included patients with confirmed diagnosis of glioblastoma treated from 2011 to 2016. TRT was defined as the time between surgery (biopsy or resection) and the first day of radiation therapy. The endpoint was OS. The patients were divided according to the TRT in three categories: < 30 days, 30-60 days and ≥ 60 days. RESULTS: A total of 134 patients were included with a mean age of 51.82 years (range 19-78 years). Median TRT was 80 days. On univariate and multivariable analysis, we identified age as the only significant independent predictor for OS. There was no statistically significant negative impact of TRT on OS (p = 0.47). CONCLUSIONS: There was no clear evidence that delaying post-operative combined chemoradiotherapy negatively impacts OS, not even for TRT longer than 60 days.
Authors: T Hoshino; S Ito; A Asai; M Shibuya; M D Prados; B A Dodson; R L Davis; C B Wilson Journal: Int J Cancer Date: 1992-01-02 Impact factor: 7.396
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Deborah T Blumenthal; Minhee Won; Minesh P Mehta; Walter J Curran; Luis Souhami; Jeff M Michalski; C Leland Rogers; Benjamin W Corn Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Thierry Gorlia; Martin J van den Bent; Monika E Hegi; René O Mirimanoff; Michael Weller; J Gregory Cairncross; Elizabeth Eisenhauer; Karl Belanger; Alba A Brandes; Anouk Allgeier; Denis Lacombe; Roger Stupp Journal: Lancet Oncol Date: 2007-12-21 Impact factor: 41.316
Authors: Domenique M J Müller; Merijn E De Swart; Hilko Ardon; Frederik Barkhof; Lorenzo Bello; Mitchel S Berger; Wim Bouwknegt; Wimar A Van den Brink; Marco Conti Nibali; Roelant S Eijgelaar; Julia Furtner; Seunggu J Han; Shawn Hervey-Jumper; Albert J S Idema; Barbara Kiesel; Alfred Kloet; Emmanuel Mandonnet; Pierre A J T Robe; Marco Rossi; Tommaso Sciortino; W Peter Vandertop; Martin Visser; Michiel Wagemakers; Georg Widhalm; Marnix G Witte; Philip C De Witt Hamer Journal: Neurooncol Adv Date: 2021-04-08